NEW YORK – Thermo Fisher Scientific said on Tuesday that is has partnered with Mindray to offer drug screening technology to clinical and drug court laboratories in the US and Canada.
Under the exclusive agreement, the firms are offering Mindray's BS-480 and BA-800M analyzers, which are cleared by the US Food and Drug Administration and approved by Health Canada, together with Thermo Fisher's DRI and CEDIA drugs of abuse immunoassay reagents for screening urine samples for certain drugs. Thermo Fisher began distributing, installing, training, and servicing Mindray instruments in labs in the US and Canada last month.
"Now we can better cater to the needs of those laboratories seeking to expand or increase their testing volumes and laboratories working to consolidate and centralize their testing sites with these two medium- to high-throughput instruments," said Stefan Wolf, president of the clinical diagnostics business at Thermo Fisher Scientific, in a statement.